IGIV as a possible treatment for Alzheimer's
.
Alzheimer's Donation
Donate Online Now
.
Baxter International Inc. (NYSE: BAX) and The Alzheimer's Disease Cooperative Study (ADCS) group today announced the decision to pursue a multi-center U.S. Phase III study evaluating the role of Gammagard Liquid [Immune Globulin Intravenous (Human)] (IGIV), an intravenous immunoglobulin preparation, for the treatment of patients with mild to moderate alzheimer's disease. GAMMAGARD Liquid contains a broad spectrum of immunoglobulins (antibodies), and is indicated as an immunoglobulin replacement therapy in patients with primary immunodeficiency.
GAMMAGARD Liquid is processed from large pools of human plasma. IGIV has been used for almost three decades to treat primary immunodeficiency. IGIV is not currently approved for the treatment of Alzheimer's disease, and to date has not been established to be effective in this indication. The rationale for testing IGIV as a possible treatment for Alzheimer's is based on the presence of natural antibodies that are directed against several forms of beta amyloid. Beta amyloid is a protein found in plaques that accumulate in the brains of patients with Alzheimer's disease, and is considered to play a key role in the cognitive decline observed in these patients. Treatment with naturally occurring antibodies against beta amyloid contained in IGIV may result in clearance of beta amyloid from the brain and dissolution of plaques.
[Immune Globulin Intravenous (Human)] 10% GAMMAGARD LIQUID is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
Omega-3 encapsulation in chitosan gets study boost
Chitosan plus maltodextrin could offer an interesting alternative for the encapsulation of omega-3 rich fish oils, suggests a new study that uses a novel ultrasonic technique to generate impressive results.
posted YVN
.
Alzheimer's Donation
Donate Online Now
.
Baxter International Inc. (NYSE: BAX) and The Alzheimer's Disease Cooperative Study (ADCS) group today announced the decision to pursue a multi-center U.S. Phase III study evaluating the role of Gammagard Liquid [Immune Globulin Intravenous (Human)] (IGIV), an intravenous immunoglobulin preparation, for the treatment of patients with mild to moderate alzheimer's disease. GAMMAGARD Liquid contains a broad spectrum of immunoglobulins (antibodies), and is indicated as an immunoglobulin replacement therapy in patients with primary immunodeficiency.
GAMMAGARD Liquid is processed from large pools of human plasma. IGIV has been used for almost three decades to treat primary immunodeficiency. IGIV is not currently approved for the treatment of Alzheimer's disease, and to date has not been established to be effective in this indication. The rationale for testing IGIV as a possible treatment for Alzheimer's is based on the presence of natural antibodies that are directed against several forms of beta amyloid. Beta amyloid is a protein found in plaques that accumulate in the brains of patients with Alzheimer's disease, and is considered to play a key role in the cognitive decline observed in these patients. Treatment with naturally occurring antibodies against beta amyloid contained in IGIV may result in clearance of beta amyloid from the brain and dissolution of plaques.
[Immune Globulin Intravenous (Human)] 10% GAMMAGARD LIQUID is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
Omega-3 encapsulation in chitosan gets study boost
Chitosan plus maltodextrin could offer an interesting alternative for the encapsulation of omega-3 rich fish oils, suggests a new study that uses a novel ultrasonic technique to generate impressive results.
posted by Valery Yermalitsky at
6:59 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home